

# **Polyhealth Medical Inc.**

## **Annual Financial Statements**

For the Years Ended March 31, 2025 and Period Ended March 31, 2024

# Polyhealth Medical Inc.

## Annual Financial Statements

For the Years Ended March 31, 2025 and Period Ended March 31, 2024

### Table of Contents

Particulars	Page No.
<b>ANNUAL FINANCIAL STATEMENTS</b>	
Balance Sheet	3
Statement of Income from Operations	4
Statement of Changes in Shareholder's Equity	5
Statement of Cash Flows	6
Notes to Annual Financial Statements	7-10

Polyhealth Medical Inc.  
Balance Sheet  
As of March 31, 2025 and March 31, 2024

Particulars	As of March 31, 2025	As of March 31, 2024
<b>Assets</b>		
<b>Current Assets</b>		
Cash and Cash Equivalents	45,394	19,146
Accounts Receivables	23,754	-
Other Current Assets	16,267	15,705
<b>Total Current Assets</b>	<b>85,415</b>	<b>34,851</b>
<b>Non-Current Assets</b>		
Deferred Tax Asset	285,962	267,629
Less: Valuation Allowance	(285,962)	-
	-	267,629
Other Non-Current Assets	-	-
<b>Total Non-Current Assets</b>	<b>-</b>	<b>267,629</b>
<b>Total Assets</b>	<b>85,415</b>	<b>302,480</b>
<b>Liabilities and Shareholders' Equity</b>		
<b>Current Liabilities</b>		
Accounts Payable	99,555	-
Accrued Expenses	-	-
Other Current Liabilities	-	20,884
<b>Total Current Liabilities</b>	<b>99,555</b>	<b>20,884</b>
<b>Total Liabilities</b>	<b>99,555</b>	<b>20,884</b>
<b>Shareholders' Equity</b>		
Equity	1,201,875	914,875
Retained Earnings	(633,279)	(583,660)
Net Income/(Loss)	(582,736)	(49,619)
<b>Total Shareholders' Equity</b>	<b>(14,140)</b>	<b>281,596</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>85,415</b>	<b>302,480</b>

See accompanying notes to financial statements.

**Polyhealth Medical Inc.**  
**Statement of Income from Operations**  
**For the Year Ended March 31, 2025 and Period Ended March 31, 2024**

<b>Particulars</b>	<b>For the Year Ended March 31, 2025</b>	<b>For the Period Ended March 31, 2024</b>
Revenue	104,775	-
Cost of Service	105,565	-
<b>Gross Profit/ (Loss)</b>	<b>(790)</b>	<b>-</b>
<b>Operating Expenses</b>		
Selling, General and Administrative Expenses	126,845	23,896
Employee Benefit Expenses	192,907	37,105
Finance Charges	575	125
<b>Total Operating Expenses</b>	<b>320,327</b>	<b>61,126</b>
<b>Other Expense/(Income)</b>		
Other Expense	-	9,540
Other Income	6,010	-
<b>Total Other Expense/(Income)</b>	<b>(6,010)</b>	<b>9,540</b>
<b>Loss Before Income Taxes</b>	<b>(315,107)</b>	<b>(70,666)</b>
<b>Income Taxes</b>		
Provision for Income Tax	-	-
Deferred Tax Expense	285,962	-
Deferred Tax (Benefit)	(18,333)	21,047
<b>Total Income Taxes</b>	<b>267,629</b>	<b>21,047</b>
<b>Net Income/(Loss)</b>	<b>(582,736)</b>	<b>(49,619)</b>

*See accompanying notes to financial statements.*

**Polyhealth Medical Inc.**

**Statement of Changes in Shareholders' Equity**

**For the Year Ended March 31, 2025 and Period Ended March 31, 2024**

Particulars	Shareholders' Equity	Additional Paid in Capital	Net Income	Retained Earnings	Total Accumulated Surplus / (Deficit)
<b>Balance at the beginning of the period</b>	<b>\$ 10</b>	<b>\$ 864,915</b>	<b>(37,081)</b>	<b>(546,579)</b>	<b>281,265</b>
Additions during the period	-	49,950	-	-	49,950
Adjustments during the period	-	-	-	-	-
Transfer of Previous Period Net Income to Retained Earnings	-	-	37,081	(37,081)	-
Net Income/(Loss) for the Year ended March 31, 2024	-	-	(49,619)	-	(49,619)
<b>Balances as of March 31, 2024</b>	<b>\$ 10</b>	<b>\$ 914,865</b>	<b>\$ (49,619)</b>	<b>\$ (583,660)</b>	<b>281,596</b>
Adjustments during the period	990	(990)	-	-	-
Additions during the period	-	287,000	-	-	287,000
Transfer of Previous Period Net Income to Retained Earnings	-	-	49,619	(49,619)	-
Net Income/(Loss) for the Year Ended March 31, 2025	-	-	(582,736)	-	(582,736)
<b>Balances as of March 31, 2025</b>	<b>\$ 1,000</b>	<b>\$ 1,200,875</b>	<b>\$ (582,736)</b>	<b>\$ (633,279)</b>	<b>(14,140)</b>

**Note:** The corporation is authorized to issue 3,000,000 number of shares with a US\$ 1 per share as per Delaware 'Certificate of Amendment' filed on February 27, 2025. Before the amendment, the corporation is authorised to issue 1,000 shares at USD 0.01 per share.

*See accompanying notes to financial statements.*

**Polyhealth Medical Inc.**  
**Statement of Cash Flows**  
**For the Year Ended March 31, 2025 and Period Ended March 31, 2024**

Particulars	For the Year Ended March 31, 2025	For the Period Ended March 31, 2024
<b>Cash Flows From Operating Activities</b>		
Net Income	(582,736)	(49,619)
<b>Adjustments to Reconcile Net Income to Net Cash used in Operating Activities</b>		
Deferred Tax (Benefit)/Expense	267,629	(21,047)
<b>Changes in Operating Assets and Liabilities</b>		
(Increase)/Decrease in Other Current Assets	(562)	8,074
(Increase)/Decrease in Accounts Receivable	(23,754)	5,191
(Increase)/Decrease in Other Non Current Assets	-	-
Increase/(Decrease) in Accounts Payable	99,555	(16,142)
Increase/(Decrease) in Accrued Expenses	-	-
Increase/(Decrease) in Other Current Liabilities	(20,884)	11,384
<b>Net Cash Provided/(Used) By Operating Activities</b>	<b>(260,751)</b>	<b>(62,158)</b>
<b>Cash Flows From Investing Activities</b>		
Proceeds from sale of Fixed Assets	-	-
<b>Net Cash Provided/(Used) By Investing Activities</b>	<b>-</b>	<b>-</b>
<b>Cash Flows From Financing Activities</b>		
Introduction of Capital Stock	287,000	49,950
<b>Net Cash Provided/(Used) By Financing Activities</b>	<b>287,000</b>	<b>49,950</b>
Net Increase (Decrease) in Cash and Cash Equivalents	26,249	(12,208)
Cash and Cash Equivalents at Beginning of the Period	19,146	31,354
<b>Cash and Cash Equivalents at the End of the Period</b>	<b>45,394</b>	<b>19,146</b>

*See accompanying notes to financial statements.*

**Note A - Organization and Operations**

Polyhealth Medical Inc. (the "Corporation") is a domestic business corporation incorporated on July 19, 2021, under the state laws of Delaware. Its registered address is 222 Village Hill Lane, Huntersville, North Carolina, USA. The corporation is engaged in the business of designing, manufacturing and selling single use disposable medical products to distributors.

Polyhealth Medical Inc. is the wholly owned subsidiary of Poly Medicure B.V., whose registered address is Kiezersgracht 391A, Amsterdam, North Holland, Netherlands-1016EJ.

**Note B - Summary of Significant Accounting Policies**

**1. Annual Financial Statements preparation**

The financial statements presented here have been prepared in accordance with the historical cost convention and on the accrual basis of accounting, as required by generally accepted accounting principles (GAAP) in the United States. These statements reflect the financial position, results of operations, and cash flows of the corporation for the calendar year ending March 31, 2025 (current year), and are presented alongside financial statements for the period January 1, 2024 to March 31, 2024 (prior short period).

Effective April 1, 2024, the Company changed its financial year-end from December 31 to March 31 to better align its reporting cycle with operational or industry-specific requirements. As a result, the comparative figures presented are for a three-month period from January 1, 2024, to March 31, 2024, whereas the current reporting period covers twelve months from April 1, 2024, to March 31, 2025.

Due to the difference in reporting periods, the financial information presented may not be directly comparable.

**2. Presentation**

The financial statements are presented in United States dollars which is the Corporation's elected reporting currency. In the opinion of management, the financial data includes all adjustments, consisting only of normal recurring adjustments, necessary to a fair statement of presentation of the results for the period.

**3. Use of Estimates**

The preparation of annual financial statements is in conformity with US GAAP, which requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The estimates and underlying assumptions are reviewed by the management at regular intervals or in case of changes in micro and macro economic factors. Revisions to accounting estimates are accounted in the same year in which revisions are finalised by the management. If the revisions are impacting future years under the circumstances, then will be accounted in the future years as well.

Management bases the estimates on a number of factors, including historical experience, current events and actions that the corporation may undertake in the future and other assumptions that the corporation believes are reasonable under the circumstances.

#### **4. Going Concern Assumption**

The financial statements have been prepared under the going concern assumption, which presumes that the corporation will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The Corporation has incurred recurring losses during the current and prior financial periods. Management is actively pursuing various strategic and operational initiatives aimed at improving the Corporation's financial position. No adjustments have been made to the financial statements relating to the carrying value of assets and liabilities.

The sole shareholder i.e. Poly Medicure B.V. has given the consent to provide the necessary funds whenever required by the corporation to mitigate the risk of going concern.

#### **5. Revenue Recognition**

The Corporation has adopted ASC 606, "Revenue from Contracts with Customers," issued by the Financial Accounting Standards Board (FASB). Revenue is recognized when control of the products or services promised to customers is transferred, in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer. Indicators that control has been transferred include, the establishment of the company's present right to receive payment for the goods sold, transfer of legal title to the customer, transfer of physical possession to the customer, transfer of significant risks and rewards of ownership in the goods to the customer, and the acceptance of the goods by the customer.

#### **6. Fair Value Considerations**

The Corporation uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is material to the fair value measurement.

The Corporation's financial instruments (primarily cash and cash equivalents, receivables and payables) are carried in the accompanying statement of financial position at amounts, which reasonably approximate fair value.



**Polyhealth Medical Inc.****Notes to Annual Financial Statements****For the Year ended March 31, 2025 and Period ended March 31, 2024****Note C- Notes to items in Balance Sheet****1. Cash and Cash Equivalents**

The corporation defines cash equivalents as short-term, highly liquid investments readily convertible to cash with original maturities of three months or less. The corporation maintained cash balances in one financial banking institution in the United States of America as of March 31, 2025. All the accounts are insured by the Federal Deposit Insurance Corporation on aggregate balances up to \$ 250,000.

**2. Accounts Receivables**

Accounts receivable represents amounts owed by the customers with respect to goods or services provided by the corporation which are expected to be collected within the next twelve months.

Particulars	As of March 31, 2025	As of March 31, 2024
Medline Industries, Inc.	23,754	-

**3. Other Current Assets**

Prepaid expenses represent payments made in advance for goods and services to be received in future periods. These amounts are recognized as assets and expensed over the period in which the related benefits are received, in accordance with US GAAP.

Particulars	As of March 31, 2025	As of March 31, 2024
Prepaid Insurance	16,267	15,705

**4. Accounts Payables**

Accounts Payables represents amounts owed by the corporation with respect to goods or services provided by the vendor which are expected to be settled within the next twelve months.

Particulars	As of March 31, 2025	As of March 31, 2024
Poly Medicare Limited	99,555	-

**5. Other Current Liabilities**

Under US GAAP, Other Current Liabilities represent current liabilities that do not fall into more specific categories such as accounts payable, accrued expenses, or short-term debt. These liabilities are expected to be settled within one year or within the corporation's operating cycle, whichever is longer.

Particulars	As of March 31, 2025	As of March 31, 2024
Advance by customers	-	20,884

**7. Income Taxes:****State Income Taxes:**

The corporation is incorporated in Delaware where the state income tax is 8.7% and registered in North Carolina as foreign entity where state income tax is 2.5%

**Federal Income Tax:**

The corporation is a C corporation for tax purposes, filing Form 1120 annually. Profits are not being passed through to owners; hence tax is paid at the corporation's level. The corporation has incurred losses of \$315,107 and \$70,666 for the period ended March 31, 2025 and March 31, 2024 respectively. Hence, no provision is created for income tax.

**Polyhealth Medical Inc.****Notes to Annual Financial Statements****For the Year ended March 31, 2025 and Period ended March 31, 2024**

Deferred tax assets and liabilities are determined based on the differences between the taxable profit in financial statement and the tax basis of assets and liabilities. Realization of the future tax benefits related to the net deferred tax assets is dependent on many factors including the Company's ability to generate taxable income.

The company has recorded a deferred tax asset related to its net operating loss carryforwards, which are expected to reduce future taxable income. The company has assessed the likelihood of realizing the deferred tax assets and determined that it is more likely than not that a portion of the assets will not be realized. Therefore, a valuation allowance has been created to account for 100% of the deferred tax assets to its deferred tax assets to its expected realizable value.

During the period deferred taxes have been calculated as follows:

Particulars	For the year ended March 31, 2025	For the period ended March 31, 2024
Deferred Tax Benefit	(18,333)	(21,047)
Deferred Tax Expense	285,962	-
<b>Total</b>	<b>267,629</b>	<b>(21,047)</b>

Particulars	For the year ended March 31, 2025	For the period ended March 31, 2024
Deferred Tax Asset/ (Liabilities)	285,962	267,629
Less : Valuation Allowance	(285,962)	-
<b>Total</b>	<b>-</b>	<b>267,629</b>

**Note D - Reclassification of Prior Year Amounts**

No reclassifications of prior year amounts have been made, as the current year presentation is consistent with prior periods.

**Note E – Inter Company, Related Party and Affiliates Disclosure Information**

A related party transaction is a transaction which takes place between two parties and between the corporation and its affiliates / related party through relative of the member who owns the corporation and by having the common or significant control/interest.

**Intercompany balances**

Related Party	Account type	For the year ended March 31, 2025	For the period ended March 31, 2024
Poly Medicare Limited	Accounts Payable	99,555	-
Poly Medicare B.V.	Capital Contribution	1,201,875	914,875

**Note F - Contingencies & Lawsuits**

There were no contingencies or lawsuits pending as of March 31, 2025 (Previous Year - \$ NIL)

**Note G– Subsequent Events**

Subsequent events are events or transactions that occur after the statement of financial position date but before the financial statements are issued. The corporation recognizes the effects of subsequent events that provide additional information about conditions that existed at the date of the statement of financial positions. No events have occurred subsequent to March 31, 2025 that requires recording or disclosure in the financial statements.